Impact of pre-existent vascular and poly-vascular disease on acute myocardial infarction management and outcomes: An analysis of 2 million patients from the National Inpatient Sample.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
15 03 2021
Historique:
received: 18 09 2020
revised: 13 11 2020
accepted: 23 11 2020
pubmed: 4 12 2020
medline: 29 5 2021
entrez: 3 12 2020
Statut: ppublish

Résumé

Patients with pre-existing vascular disease are known to have worse outcomes after acute myocardial infarction (AMI). However, there is limited data for outcomes stratified by type and number of vascular territories involved. Using the Nationwide Inpatient Sample (2015-2017), we examined outcomes of AMI in patients with pre-existent vascular disease stratified by number as well as types of diseased beds including all five major vascular sites: cardiac, cerebrovascular, renal, aortic and peripheral vascular disease (PVD). Multivariable logistic regression was used to determine the adjusted odds ratios (aOR) of adverse outcomes and invasive procedure utilization. Out of 2,184,614 AMI admissions, 49.7% had pre-existent vascular disease. The odds of major adverse cardiovascular and cerebrovascular events (MACCE), mortality, ischemic stroke and major bleeding incrementally increased and was highest in those with ≥3 vascular sites involved (aOR for MACCE 1.16, CI 1.13-1.19; mortality 1.3, CI 1.26-1.34; stroke 1.15, CI 1.1-1.2; major bleeding 1.21, CI 1.16-1.25). Amongst those with a single pre-existent diseased vascular bed, the adjusted odds of MACCE appeared to be higher in those with PVD (1.28, CI 1.26-1.31), aortic disease (1.24, CI 1.19-1.29), and cerebrovascular disease (1.22, CI 1.2-1.25). Patients with pre-existent vascular disease had a lower overall likelihood of undergoing invasive revascularization procedures. Approximately half of the population presenting with AMI have pre-existent vascular disease. There is an incremental increase in adverse outcomes with increasing number of diseased vascular beds, with further differences in outcomes and utilization of invasive procedures based on sub-types of sites involved.

Sections du résumé

BACKGROUND
Patients with pre-existing vascular disease are known to have worse outcomes after acute myocardial infarction (AMI). However, there is limited data for outcomes stratified by type and number of vascular territories involved.
METHODS
Using the Nationwide Inpatient Sample (2015-2017), we examined outcomes of AMI in patients with pre-existent vascular disease stratified by number as well as types of diseased beds including all five major vascular sites: cardiac, cerebrovascular, renal, aortic and peripheral vascular disease (PVD). Multivariable logistic regression was used to determine the adjusted odds ratios (aOR) of adverse outcomes and invasive procedure utilization.
RESULTS
Out of 2,184,614 AMI admissions, 49.7% had pre-existent vascular disease. The odds of major adverse cardiovascular and cerebrovascular events (MACCE), mortality, ischemic stroke and major bleeding incrementally increased and was highest in those with ≥3 vascular sites involved (aOR for MACCE 1.16, CI 1.13-1.19; mortality 1.3, CI 1.26-1.34; stroke 1.15, CI 1.1-1.2; major bleeding 1.21, CI 1.16-1.25). Amongst those with a single pre-existent diseased vascular bed, the adjusted odds of MACCE appeared to be higher in those with PVD (1.28, CI 1.26-1.31), aortic disease (1.24, CI 1.19-1.29), and cerebrovascular disease (1.22, CI 1.2-1.25). Patients with pre-existent vascular disease had a lower overall likelihood of undergoing invasive revascularization procedures.
CONCLUSIONS
Approximately half of the population presenting with AMI have pre-existent vascular disease. There is an incremental increase in adverse outcomes with increasing number of diseased vascular beds, with further differences in outcomes and utilization of invasive procedures based on sub-types of sites involved.

Identifiants

pubmed: 33271206
pii: S0167-5273(20)34220-0
doi: 10.1016/j.ijcard.2020.11.051
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-8

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declared that they have no conflict of interest.

Auteurs

Ofer Kobo (O)

Department of Cardiology, Hillel Yaffe Medical Center, Hadera, Israel; Keele Cardiovascular Research Group, Keele University, UK.

Tahmeed Contractor (T)

Division of Cardiology, Department of Medicine, Loma Linda University Health, Loma Linda, CA, United States of America.

Mohamed O Mohamed (MO)

Keele Cardiovascular Research Group, Keele University, UK; Royal Stoke Hospital, Stoke on Trent, UK.

Purvi Parwani (P)

Division of Cardiology, Department of Medicine, Loma Linda University Health, Loma Linda, CA, United States of America.

Timir K Paul (TK)

East Tennessee State University, TN, USA.

Raktim K Ghosh (RK)

MedStar Heart and Vascular Institute, Union Memorial Hospital, Baltimore, MD, USA.

M Chadi Alraes (MC)

Detroit Medical Center, Wayne State University, United States of America.

Brijesh Patel (B)

Division of Cardiology, West Virginia University School of Medicine, Morgantown, WV, USA.

Mohammed Osman (M)

Division of Cardiology, West Virginia University School of Medicine, Morgantown, WV, USA.

Josef Ludwig (J)

Division of Cardiology, Department of Medicine, Loma Linda University Health, Loma Linda, CA, United States of America.

Ariel Roguin (A)

Department of Cardiology, Hillel Yaffe Medical Center, Hadera, Israel.

Mamas A Mamas (MA)

Keele Cardiovascular Research Group, Keele University, UK; Royal Stoke Hospital, Stoke on Trent, UK; Department of Cardiology, Thomas Jefferson University, USA. Electronic address: mamasmamas1@yahoo.co.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH